The use of isotopes in the determination of absolute bioavailability of drugs in humans

Bibliography

• FDA US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Code of Federal Regulations, Title 21, Subchapter D Drugs for Human Use, part 320 Bioavailability and Bioequivalence Requirements.
   Google Scholar
• FDA US DEPARTMENT OF HEALTH AND HUMAN SERVICES: CDER, Waiver of invivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceuticals classification system.
   Google Scholar
• CHEN ML, SHAH V, PATNAIK R etal.: Bioavailability and bioequivalence: an FDA regulatory overview. Pharm. Res. (2001) 18(12):1645-1650.
   PubMed Web of Science ®Google Scholar
• RAJARAM L, ROY SK, SKERJANEC A: Bioavailability and bioequivalence trials: statistics and pharmacokinetic principles. Stud. Health Technol. Inform. (2004) 103:159-179.
   PubMedGoogle Scholar
• JUSKO WJ, KOUP JR, ALVAN G: Nonlinear assessment of phenytoin bioavailability. J. Pharmacokinet. Biopharm. (1976) 4(4):327-336.
   PubMedGoogle Scholar
• RUBIN GM, TOZER TN: Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics. J. Pharmacokinet. Biopharm. (1984) 12(4):437-450.
   PubMedGoogle Scholar
• RUBIN GM, WASCHEK JA, POND SM, EFFENEY DJ, TOZER TN: Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J. Pharmacokinet. Biopharm. (1987) 15(6):615-631.
   PubMedGoogle Scholar
• STRONG JM, DUTCHER JS, LEE WK, ATKINSON AJ: Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin. Pharmacol. Ther. (1975) 18(5Pt1):613-622.
   PubMed Web of Science ®Google Scholar
• SCHEINER S: Calculation of isotope effects from first principles. Biochim. Biophys. Acta (2000) 1458(1):28-42.
   PubMed Web of Science ®Google Scholar
• CLELAND WW: The use of isotope effects to determine enzyme mechanisms. Arch. Biochem. Biophys. (2005) 433(1):2-12.
   PubMed Web of Science ®Google Scholar
• ROESKE CA, OLEARY MH: Carbon isotope effect on carboxylation of ribulose bisphosphate catalyzed by ribulosebisphosphate carboxylase from Rhodospirillum rubrum. Biochemistry (1985) 24(7):1603-1607.
   PubMed Web of Science ®Google Scholar
• ANDERSEN ME, CLEWELL HJ, MAHLE DA, GEARHART JM: Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice invivo. Toxicol. Appl. Pharmacol. (1994) 128(1):158-165.
   PubMed Web of Science ®Google Scholar
• BROWNE TR, SZABO GK, MCENTEGART C etal.: Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique. J. Clin. Pharmacol. (1993) 33(1):89-94.
   PubMed Web of Science ®Google Scholar
• PIENIASZEK HJ, MAYERSOHN M, ADAMS MP, REINHART RJ, BARRETTRS: Moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implications. J. Clin. Pharmacol. (1999) 39(8):817-825.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN H, SARAHEIMO M, ANTILA S, OTTOILA P, PENTIKAINENPJ: Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur. J. Clin. Pharmacol. (2001) 56(11):821-826.
   PubMed Web of Science ®Google Scholar
• PRESTON SL, DRUSANO GL, GLUE P, NASH J, GUPTA SK, MCNAMARA P: Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob. Agents Chemother. (1999) 43(10):2451-2456.
   PubMed Web of Science ®Google Scholar
• HAGE K, BUHL K, FISCHER C, KNEBEL NG: Estimation of the absolute bioavailability of flecainide using stable isotope technique. Eur. J. Clin. Pharmacol. (1995) 48(1):51-55.
   PubMed Web of Science ®Google Scholar
• DILGER K, ECKHARDT K, HOFMANN U, KUCHER K, MIKUS G, EICHELBAUM M: Chronopharmacology of intravenous and oral modified release verapamil. Br. J. Clin. Pharmacol. (1999) 47(4):413-419.
   PubMed Web of Science ®Google Scholar
• HECK HA, BUTTRILL SE, FLYNN NW etal.: Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests. J. Pharmacokinet. Biopharm. (1979) 7(3):233-248.
   PubMedGoogle Scholar
• RICHARD J, CARDOT JM, GODBILLON J: Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations. Eur. J. Drug Metab. Pharmacokinet. (1994) 19(4):375-380.
   PubMed Web of Science ®Google Scholar
• SUN JX, PIRAINO AJ, MORGAN JM etal.: Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. J. Clin. Pharmacol. (1995) 35(4):390-397.
   PubMed Web of Science ®Google Scholar
• BROWNE TR: Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin. Pharmacokinet. (1990) 18(6):423-433.
   PubMed Web of Science ®Google Scholar
• LAPPIN G, GARNER RC: Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Handbook of Bioanalytical Separations. I Wilson (Ed.), Elsevier Science, Amsterdam, The Netherlands (2003):331-349.
   Google Scholar
• LAPPIN G, GARNER RC: Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. (2004) 378(2):356-364.
   PubMed Web of Science ®Google Scholar
• WHITBY B: Quantitative whole body autoradiography. In: Radiotracers in drug development. G Lappin, S Temple (Eds), Taylor Francis CRC Press, Florida, USA (2006).
   Google Scholar
• MIHALY GW, WARD SA, EDWARDS G, NICHOLL DD, ORME ML, BECKENRIDGE AM: Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. (1985) 19(6):745-750.
   PubMed Web of Science ®Google Scholar
• ANDERSSON T, ANDREN K, CEDERBERG C, LAGERSTROM PO, LUNDBORG P, SKANBERG I: Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. (1990) 29(5):557-563.
   PubMed Web of Science ®Google Scholar
• LIMA JJ, HAUGHEY DB, LEIER CV: Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. J. Pharmacokinet. Biopharm. (1984) 12(3):289-313.
   PubMedGoogle Scholar
• COTLER S, BUGGE CJ, COLBURNWA: Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. Drug Metab. Dispos. (1983) 11(5):458-462.
   PubMed Web of Science ®Google Scholar
• WOOD AJJ, KORNHAUSER DM, WILKINSON GR, SHAND DG, BRANCH RA: The influence of cirrhosis on steady-state blood concentrations of unbound proprnolol after oral administration. Clin. Pharmacokinet. (1978) 3:478-487.
   PubMed Web of Science ®Google Scholar
• SARAPA N, HSYU PH, LAPPIN G, GARNER RC: The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. (2005) 45(10):1198-1205.
   PubMed Web of Science ®Google Scholar
• LIBERMAN RG, TANNENBAUM SR, HUGHEY BJ etal.: An interface for direct analysis of 14C in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. (2004) 76(2):328-334.
   PubMed Web of Science ®Google Scholar
• KLEM B, LAPPIN G, NICHOLSON S etal.: Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J. Clin. Pharmacol. (2006) 46(4):456-460.
   PubMed Web of Science ®Google Scholar
• KWAN KC: Oral bioavailability and first-pass effects. Drug Metab. Dispos. (1997) 25(12):1329-1336.
   PubMed Web of Science ®Google Scholar
• LAPPIN G, GARNER RC: The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. (2005) 1(1):23-32.
   PubMedGoogle Scholar
• KUPPENS IE, BREEDVELD P, BEIJNENJH, SCHELLENS JH: Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest. (2005) 23(5):443-464.
   PubMed Web of Science ®Google Scholar